Mei pharma, inc. (MEIP)
Income statement / Yearly
Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11
Revenue

4,915

1,622

23,249

-

-

-

-

-

-

Operating expenses:
Cost of revenue

4,263

3,383

5,000

-

-

-

-

-

-

Research and development

32,300

17,038

7,237

13,403

23,823

19,331

6,084

4,915

2,115

General and administrative

14,597

9,787

8,628

7,601

8,948

7,897

5,138

3,479

4,336

Total operating expenses

51,160

30,208

20,865

21,004

32,771

-

-

-

-

Total operating expenses

-

-

-

-

-

27,228

11,222

8,394

6,451

Loss from operations

-46,245

-28,586

2,384

-21,004

-32,771

-27,228

-11,222

-8,394

-6,451

Other income (expense):
Change in fair value of warrant liability

27,632

-9,705

-

-

-

-

-

-

-

Financing costs associated with warrants

-

2,367

-

-

-

-

-

-

-

Interest and dividend income

1,795

591

287

143

78

81

37

39

130

Fair value of derivative liabilities in excess of proceeds

-

-

-

-

-

-

-

-

-508

Adjustments to fair value of derivatives

-

-

-

-

-

-

-

1,139

49

Financing costs

-

-

-

-

-

-

-

406

-

Gain on sale of investment

-

-

-

-

-

-

-

100

-

Income tax expense

1

1

1

1

1

1

1

1

1

Net loss

-16,819

-40,068

2,670

-20,862

-32,694

-27,148

-11,186

-7,523

-

Net loss:
Basic

-16,819

-40,068

2,670

-

-

-

-

-

-

Diluted

-54,613

-40,068

2,670

-

-

-

-

-

-

Net loss per share:
Net loss arising during development stage

-

-

-

-

-

-

-

-

-6,781

Basic and diluted

-

-

-

-

-

-1.35

-1.10

-3.35

-0.89

Basic

-0.24

-0.97

0.07

-0.61

-1.16

-

-

-

-

Diluted

-0.75

-0.97

0.07

-0.61

-1.16

-

-

-

-

Shares used in computing net loss per share:
Basic

71,139

41,431

36,813

34,400

28,204

-

-

-

-

Diluted

72,385

41,431

36,938

34,400

28,204

-

-

-

-

Basic and diluted

-

-

-

-

-

20,061

10,160

2,247

7,643